Perrigo (PRGO) Total Non-Current Liabilities (2013 - 2026)
Perrigo (PRGO) posted quarterly Total Non-Current Liabilities of $4.5 billion for Q1 2026, up 3.82% year-over-year from $4.3 billion in Q1 2025, and down 2.18% quarter-over-quarter from $4.6 billion in Q4 2025.
Perrigo (PRGO) Total Non-Current Liabilities (2013 - 2026) Analysis & Trends
Perrigo (PRGO) has reported Total Non-Current Liabilities for 14 consecutive years, with $4.5 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 3.82% year-over-year to $4.5 billion; the TTM figure through Mar 2026 stood at $4.5 billion (up 3.82% YoY), while the FY2025 annual figure was $4.6 billion, up 7.07% from the prior year.
- Total Non-Current Liabilities declined to $4.5 billion in Q1 2026 per PRGO's latest filing, from $4.6 billion in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $5.2 billion in Q3 2024 and bottomed at $4.3 billion in Q4 2024.
- Historically, Total Non-Current Liabilities has averaged $4.7 billion across 5 years, with a median of $4.5 billion in 2025.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities soared 37.32% — and 2024, when it fell 13.74%.
- Perrigo's Total Non-Current Liabilities stood at $5.1 billion in 2022, then slipped by 11.99% to $4.5 billion in 2023, then fell by 3.83% to $4.3 billion in 2024, then grew by 7.07% to $4.6 billion in 2025, then decreased by 2.18% to $4.5 billion in 2026.
- Business Quant data shows PRGO's Total Non-Current Liabilities at $4.5 billion in Q1 2026, $4.6 billion in Q4 2025, and $4.5 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 334.00 Mn |
| 10 | Perrigo | 1.91 Bn | 1.51 Bn | 313.90 Mn | 4.04 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 27, 2026 | 4.04 Bn |
| Mar 28, 2026 | 4.49 Bn |
| Dec 31, 2025 | 4.59 Bn |
| Sep 27, 2025 | 4.49 Bn |
| Jun 28, 2025 | 4.50 Bn |
| Mar 29, 2025 | 4.32 Bn |
| Dec 31, 2024 | 4.28 Bn |
| Sep 28, 2024 | 5.19 Bn |
| Jun 29, 2024 | 4.36 Bn |
| Mar 30, 2024 | 4.40 Bn |
| Dec 31, 2023 | 4.45 Bn |
| Sep 30, 2023 | 5.01 Bn |
| Jul 1, 2023 | 5.06 Bn |
| Apr 1, 2023 | 5.03 Bn |
| Dec 31, 2022 | 5.06 Bn |
| Oct 1, 2022 | 5.06 Bn |
| Jul 2, 2022 | 5.06 Bn |
| Apr 2, 2022 | 4.30 Bn |
| Dec 31, 2021 | 3.69 Bn |
| Oct 2, 2021 | 3.73 Bn |